Simona Manni
Rome, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
CD19 antigen: from tumor target to safety switch in CAR-T cell therapy.
Journal: Haematologica
Published: April 07, 2026
An in vivo CRISPR screen unveils promising target genes to improve CAR-T cell efficacy in a solid tumor model.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: January 15, 2026
Truncated form of human CD19 antigen as a suicide gene to control T-cell alloreactivity: ΔCD19.
Journal: Haematologica
Published: January 13, 2025
Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells.
Journal: Journal of hematology & oncology
Published: July 11, 2024
Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma.
Journal: Nature medicine
Published: February 09, 2024
GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 21, 2023
Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia.
Journal: Journal of hematology & oncology
Published: August 22, 2022
Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies.
Journal: Nature communications
Published: March 23, 2022
Inclusion of the Inducible Caspase 9 Suicide Gene in CAR Construct Increases Safety of CAR.CD19 T Cell Therapy in B-Cell Malignancies.
Journal: Frontiers in immunology
Published: August 09, 2021
Strategy to prevent epitope masking in CAR.CD19+ B-cell leukemia blasts.
Journal: Journal for immunotherapy of cancer
Published: May 08, 2021
PD-1-induced T cell exhaustion is controlled by a Drp1-dependent mechanism.
Journal: Molecular oncology
Published: February 18, 2021
Last Updated: 09/26/2026